Ziopharm’s Future Uncertain After Poor PICASSO Results
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
The oncology company ends development of its Phase III candidate in soft tissue sarcoma after progression-free survival data fail to live up to earlier expectations. The company will now refocus on its mid-stage pipeline.